Puma Biotechnology's NERLYNX® Included in NCCN Clinical Practice Guidelines for ... - BioSpace
Puma Biotechnology announced NCCN updated cervical cancer guidelines to include neratinib monotherapy for HER2-mutated tumors, based on Phase II SUMMIT trial results. This addition aims to improve treatment options for recurrent or metastatic disease.
Related Clinical Trials
Highlighted Terms
Related News
Puma Biotechnology's NERLYNX® Included in NCCN Clinical Practice Guidelines for ... - BioSpace
Puma Biotechnology announced NCCN updated cervical cancer guidelines to include neratinib monotherapy for HER2-mutated tumors, based on Phase II SUMMIT trial results. This addition aims to improve treatment options for recurrent or metastatic disease.